CrystalO Biopharma key facts
- Manufacturer of membrane protein drugs intended for neuropsychiatric disorders, chronic kidney disease and cardiovascular disease.
- It has raised $17.1M; the latest was Later Stage VC in Sep 2025.
- Notable investors include Guangdong Technology Financial Group, Goldport Capital, Fuho Capital, HitGen, Longmen Capital — 9 tracked in total.
- Status: Privately Held (backing).
- ·Watch CrystalO Biopharma: the Monday email on marks, rounds and moves
CrystalO Biopharma funding rounds
No funding rounds for CrystalO Biopharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
CrystalO Biopharma investors
9 investors are on record for CrystalO Biopharma, including Guangdong Technology Financial Group, Goldport Capital, Fuho Capital and HitGen.
About CrystalO Biopharma
Manufacturer of membrane protein drugs intended for neuropsychiatric disorders, chronic kidney disease and cardiovascular disease. The company specailises in ion channel activity testing platforms, AI-based drug discovery tools, structure-guided compound design systems, preclinical validation models and molecular screening technologies, thereby improving therapeutic precision, accelerating drug development, and enhancing patient outcomes through technological innovation.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2019
- Website
- crystalobio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
CrystalO Biopharma doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.